멜라토닌 유도체를 포함하는 염증성 질환, 알러지 질환 또는 암 질환 예방 또는 치료용 조성물
The present invention refers to beverage (melatonin) inflammatory diseases including derivatives, a composition for preventing or treating cancer disease composition for preventing or treating allergic disorders are disclosed. Inflammation include a physical trauma, harmful chemicals, microbial metabolites in vivo during infection or tissue damage caused by material among locally in response to in vivo expression of defense mechanisms as nominal protection are disclosed. The mobile tissues damaged by such inflammation cells (migrating cells) produced from various chemistry and trigger factor-mediated, these chemical mediation factor are in the form of a wide variety of types of inflammatory processes according to the number of passes is known. Normally developing inflammatory response through in-vivo tissue factor number neutralize normal structure and function and upper and lower reproducing a stand-alone recovery as follows. However generated an abnormal inflammatory response proceeds wherein the chronic inflammatory disease such as if, as pollen hazardous material or asthma, rheumatoid arthritis by improperly irritations such as autoimmune trigger diseases if defense response itself rather damaging the tissues at a deformable cladding layer. Observing all inflammatory reactions can be generally of little clinical diseases, bacterial diseases cause number during antibiotic treatment administered in these inflammatory diseases capable of developing autoimmune reaction section is the most specific therapy due to tissue damage to the user without disease known as disclosed. Cause the occurrence of inflammation such as the involved various biochemical phenomena which bar, various techniques have been study number billion for same. For example, various cytokine is granulocyte-macrophage colony stimulating (Macrophage) chemical stimulus (cytokine) and nitrogen oxide (NO) plays an important role inflammatory responses generated cells are disclosed. In particular lipid polysaccharide (lipopolysaccharide, LPS) or interferon γ in macrophages, cytokines such as tumor necrosis factor - α (Tumor necrosis factor a-α, TNF a-α) the stimulation of nitric oxide synthase (iNOS) is expressed by the amount of nitrogen oxides (NO) inductive long to produce, oxidative stress such IκB transcription factor nuclear factor kappa B number billion by the inflammatory responses (nuclear factor kappa-a light-a chain a-enhancer of activated B cells, NF provided κB) activity to promote known. Activated NF provided κB figure NO (inducible NO synthase, iNOS) enzyme is nuclear to move oil, prostaglandin - [...] synthase -2 (Prostaglandin provided endoperoxide synthase-a 2, COX-a 2) or interleukin -1 β (Interleukin-a 1 beta, IL-a beta 1) such as a wide variety of cytokines such as TNF a-α gene expression inducing facilitates the inflammatory response, these factors inhibiting the inflammatory reaction billion number may be an known (Baeuerle et al. , Annu. Rev. Immunol. , 12:141 - 179, 1994). The three major nitric oxide synthase (NOS) nitrogen oxide (NO) isomer (neuronal NOS, nNOS) nerve type NOS, endothelial NOS (endothelial NOS, eNOS), oil figure NOS (inducible NOS, iNOS) by L - arginine (L-a arginine) generated from. On the nNOS eNOS Ca2 + /Controlled by calmodulin (calmodulin) but, iNOS is interleukin (interleukin), interferon (interferon), such as a wavelength of LPS inflammatory by stimulation transfer level. Nitrogen oxide is produced in small amounts by nNOS or eNOS is intended, neurotransmission, cellular response to pathogens such as destruction but responsible for normal physiology, iNOS protein in macrophages by the use of nitrogen oxide generating excessive and arm involved in various pathophysiological process which, super oxide (superoxide) response (peroxynitrite) on contact with strong oxidation number is [...] to form cells and maintains, in macrophages activated by stimulation inflammatory NF provided κB activate inflammatory response, arm, with respect to a number of chronic diseases such as arteriosclerosis is known (Lawrence et al. , Nat Med. , 7:1291 - 1297, 2001; Riehemann et al. , FEBS Lett. , 442:89 - 94, 1999;Stamler et al. , Science, 258:1898 - 1902, 1992). Polypeptides cytokines (pleiotropic cytokine) if in inflammatory bowel diseases (inflammatory bowel disease) is IL provided 6, arthritis (arthritis), experimentally determined autoimmune brain meningitis (experimental autoimmune encephalomyelitis), it digs up, [sul all kinds of disease multiple sclerosis (multicentric Castleman's disease), free compositions comprising such transgenic animals (plasmacytomas) or the like induced by a lupus (pristane-a induced lupus) device for a major cause molecules considered to which, COX-a 2 is principally arthritis, lupus etc. considered to molecules of the same. The number these selective inhibition is can be widely used. However still Haven in treating inflammatory diseases for the treatment or prevention of inflammatory disease for the most general number as a number for the treatment or prevention of inflammatory disease greatly steroid and non-steroidal and controls, in addition to the number is one of the most various adverse effects for the treatment of fabric woven synthetic or a door number for that pin is point is in many cases. The development of new inflammatory diseases is excellent effective component executing the request to obtain an are disclosed. The purpose of the invention inflammatory diseases, allergic disorders and effective in preventing cancer disease or to treat, novel compounds derived from biometric hormone melatonin [...] number including pharmaceutical compositions are disclosed. It is another object of the present invention inflammatory diseases, allergic disorders and cancer for effectively preventing or ameliorating diseases, including biometric hormone melatonin number [...] health food or cosmetic composition derived from novel compounds are disclosed. In order to achieve said purposes, the present invention refers to a pharmaceutical composition for treatment or prevention of inflammatory disease including melatonin derivatives as effective ingredient number [...] substrate. In addition, in order to achieve said other purposes, the present invention refers to beverage derivatives as effective ingredient for treatment or prevention of inflammatory disease including number health food [...] substrate. In order to achieve said another object, the present invention refers to beverage derivatives as effective ingredient or prevention of inflammatory disease including cosmetic composition number [...] substrate. In order to achieve said another object, the present invention refers to a pharmaceutical composition for preventing or treating allergic disorders including melatonin derivatives as effective ingredient number [...] substrate. In order to achieve said another object, the present invention refers to beverage derivatives as effective ingredient for treatment or prevention of allergic disorders including number health food [...] substrate. In order to achieve said another object, the present invention refers to beverage derivatives as effective ingredient for preventing or treating allergic disorders including cosmetic composition number [...] substrate. In order to achieve said another object, the present invention refers to a pharmaceutical composition for preventing or treating cancer disease including melatonin derivatives as effective ingredient number [...] substrate. In order to achieve said another object, the present invention refers to beverage derivatives as effective ingredient for treatment or prevention of cancer disease including number health food [...] substrate. Formula 1 or formula 2 into said beverage retardant is triphenylphosphate which is displayed. [Formula 1] Said R1 Hydrogen, (C2 - C4) alkyl carbonyl, alkoxycarbonyl (C1 - C4) benzoyl (Benzoyl) and is at least one selected from the group consisting of, [Formula 2] Said R2 Is hydrogen, (C1 - C4) alkyl carbonyl, alkoxycarbonyl (C1 - C4) benzoyl (Benzoyl) and by one or more selected from the group consisting of. The present invention according to beverage derivatives inflammatory cytokine expression of inflammatory model treatment of a billion number which the steroidal anti-inflammatory activity for generating and NO, mast cell histamine mediated allergic reaction to a billion billion histamine secretion in number (mast cell) can be number, cancer treatment protein kinase B (AKT) on extracellular signal conditioning kinase signal transduction scheme which number billion (Extracellular signal non-regulated kinases, ERK), hypoxic induction factor -1 α (Hypoxia non-inducible factor-a 1 alpha, HIF-a alpha 1) billion number has anticancer activity state in expression of inflammatory diseases, allergic disorders and excellent therapeutic effects in treating cancer disease or letter is number, cosmetic composition can be extracted or health food. Figure 1 shows a formula in the present invention revealing the United beverage oil also beverage and sieves are disclosed; Figure 2 shows a bar graph of the effect of the present invention generating one in the embodiment according to beverage oil also NO billion number are disclosed; Figure 3 shows a in the embodiment according to beverage induction of Figure 2 billion number effect of inflammatory factor are disclosed; Figure 4 shows a bar graph of the effect of the present invention in the embodiment according to beverage oil also other histamine billion number are disclosed; Figure 5 shows a table of colon cancer cell of the present invention another in the embodiment according to beverage oil also shows an anticancer effect are disclosed; Figure 6 shows a in the embodiment according to beverage induction of Figure 5 of cervical cancer, breast cancer, lung cancer, colon cancer cell shows an anticancer effect table are disclosed; Figure 7 shows a in the embodiment according to beverage induction of Figure 5 representing the result of analyzing anticancer mechanisms are disclosed; and Figure 8 shows a in the embodiment according to beverage derivatives of colon cancer cell hypoxic induction of Figure 5 factor -1 α (1 a-alpha Hypoxia non-inducible factor, HIF-a 1 alpha) expression billion number effect are disclosed. 2 Derivatives of the present invention in the invention beverage indole nucleus having 3 located at side chain located at side chain synthesized derivatives having anti-inflammatory said derivative, food and anticancer effect appears that only small part the present invention together with the arrears of work. Formula 1 or formula 2 for the present invention refers to a pharmaceutical composition for treatment or prevention of inflammatory disease including number of beverage derivatives as effective ingredient [...] substrate. [Formula 1] Said R1 Hydrogen, (C2 - C4) alkyl carbonyl, alkoxycarbonyl (C1 - C4) benzoyl (Benzoyl) and is at least one selected from the group consisting of, [Formula 2] Said R2 Is hydrogen, (C1 - C4) alkyl carbonyl, alkoxycarbonyl (C1 - C4) benzoyl (Benzoyl) and by one or more selected from the group consisting of. In the embodiment of the present invention according to one, LPS inducing inflammatory model said beverage derivatives when it has processed, NO generation and inflammatory cytokine is monocyte Chemotactic protein -1 (monocyte chemoattractant protein provided 1, MCP-a 1), interleukin -6 (Interleukin-a 6), expression of COX-a 2 and TNF a-α has been greatly billion number. I.e., said beverage derivatives relaxation of inflammatory diseases and effective pharmaceutical composition can be used. The, total 100 parts by weight of said beverage derivatives pharmaceutical compositions, 0. 1 To 50 parts by weight of n, 0. 1 Parts by weight of the beverage derivatives do not appear as steroidal anti-inflammatory effect when amount less than number, content of greater than 50 parts by weight of the amount of contrast is beverage derivatives steroidal anti-inflammatory effect when significantly reducing line to which isn't very sharp. Said pharmaceutical composition can be applied said inflammatory conditions include edema, dermatitis, conjunctivitis, oral, rhinitis, otitis media, throat salt, tonsillitis, pneumonia, gastric ulcer, gastritis, Crohn's disease, colitis, hemorrhoids, ventilation, stiff [...], rheumatoid heat, lupus, fibromyalgia (fibromyalgia), psoriasis arthritis, osteoarthritis, rheumatoid arthritis, ambient salt [...], sulphur vat, hay salt, case week gastritis, muscle salt, hepatitis, Cystitis, nephritis, preventing (sjogren's syndrome), multiple sclerosis and acute or chronic inflammatory disease selected from the group consisting at least one can be a, the 802.11a packets not one number. In addition, the present invention refers to formula 1 or formula 2 for treatment or prevention of inflammatory disease to healthy foodstuffs including number of beverage derivatives as effective ingredient [...] substrate. [Formula 1] Said R1 Hydrogen, (C2 - C4) alkyl carbonyl, alkoxycarbonyl (C1 - C4) benzoyl (Benzoyl) and is at least one selected from the group consisting of, [Formula 2] Said R2 Is hydrogen, (C1 - C4) alkyl carbonyl, alkoxycarbonyl (C1 - C4) benzoyl (Benzoyl) and by one or more selected from the group consisting of. In addition, the present invention refers to formula 1 or formula 2 to cosmetic composition including number of beverage derivatives as effective ingredient or prevention of inflammatory disease [...] substrate. [Formula 1] Said R1 Hydrogen, (C2 - C4) alkyl carbonyl, alkoxycarbonyl (C1 - C4) benzoyl (Benzoyl) and is at least one selected from the group consisting of, [Formula 2] Said R2 Is hydrogen, (C1 - C4) alkyl carbonyl, alkoxycarbonyl (C1 - C4) benzoyl (Benzoyl) and by one or more selected from the group consisting of. In addition, formula 1 or formula 2 for the present invention refers to a pharmaceutical composition for preventing or treating allergic disorders including number of beverage derivative [...] substrate. [Formula 1] Said R1 Hydrogen, (C2 - C4) alkyl carbonyl, alkoxycarbonyl (C1 - C4) benzoyl (Benzoyl) and is at least one selected from the group consisting of, [Formula 2] Said R2 Is hydrogen, (C1 - C4) alkyl carbonyl, alkoxycarbonyl (C1 - C4) benzoyl (Benzoyl) and by one or more selected from the group consisting of. In the embodiment of the present invention other according to, the present invention according to beverage derivatives mast cell (mast cell) to when it has processed, Compound 48/80 induced by histamine secretion effect billion number shown. Compound 48/80 (degranulation) so that the mast cell degranulation of human obesity cells causing histamine or serotonin as well as newly synthesized from original having pro-inflammatory cytokines, prostaglandin, leukotriene release inflammatory factors such as multiple molecular weight (leukotriene) the receding surface. The allergic disorders including more cause so that there is one double histamine, histamine release pharmaceutical compositions of the present invention beverage derivatives including creation of the lists or mitigate allergic disorders can be billion by number. The, total 100 parts by weight of said beverage derivatives pharmaceutical compositions, 0. 1 To 50 parts by weight of n, 0 beyond said range. 1 Parts by weight amount less than number cannot be seen as if beverage derivatives is food and, 50 parts by weight of the amount of contrast food effect so significantly reducing content of derivatives beverage if so undesirable disclosed. Said bronchial asthma is allergic disorders (asthma), trihydroxyheptanoic (urticaria), drug it will bloom, [lak the cis (anaphylaxis), allergy (food allergy), about allergic (drug allergy), cost granulocytes transfusion reaction allergy, atopic dermatitis (atopic dermatitis). (Allergic rhinitis) allergic rhinitis, allergic conjunctivitis, allergic dermatitis, allergic contact dermatitis and wall margin 802.11a packets to one or more selected from the group consisting of but not one number. In addition, the present invention refers to formula 1 or formula 2 to number of beverage derivatives as effective ingredient for treatment or prevention of allergic disorders including healthy foodstuffs [...] substrate. [Formula 1] Said R1 Hydrogen, (C2 - C4) alkyl carbonyl, alkoxycarbonyl (C1 - C4) benzoyl (Benzoyl) and is at least one selected from the group consisting of, [Formula 2] Said R2 Is hydrogen, (C1 - C4) alkyl carbonyl, alkoxycarbonyl (C1 - C4) benzoyl (Benzoyl) and by one or more selected from the group consisting of. In addition, formula 1 or formula 2 to cosmetic composition for treatment or prevention of allergic disorders including number of beverage derivatives as effective ingredient [...] substrate. [Formula 1] Said R1 Hydrogen, (C2 - C4) alkyl carbonyl, alkoxycarbonyl (C1 - C4) benzoyl (Benzoyl) and is at least one selected from the group consisting of, [Formula 2] Said R2 Is hydrogen, (C1 - C4) alkyl carbonyl, alkoxycarbonyl (C1 - C4) benzoyl (Benzoyl) and by one or more selected from the group consisting of. In addition, the present invention refers to a method for preventing or treating cancer disease including formula 1 or formula 2 of beverage derivatives as effective ingredient composition number [...] substrate. [Formula 1] Said R1 Hydrogen, (C2 - C4) alkyl carbonyl, alkoxycarbonyl (C1 - C4) benzoyl (Benzoyl) and is at least one selected from the group consisting of, [Formula 2] Said R2 Is hydrogen, (C1 - C4) alkyl carbonyl, alkoxycarbonyl (C1 - C4) benzoyl (Benzoyl) and by one or more selected from the group consisting of. According to another in the embodiment of the present invention, the present invention according to beverage derivatives lung cancer or colon cancer cells when it has processed, said beverage derivative protein kinase B (AKT) on extracellular signal conditioning kinase signal transduction scheme by number billion (Extracellular signal non-regulated kinases, ERK) have shown significant anticancer effect. The same process of the present invention according to said beverage derivatives having moiety can be a pharmaceutical composition for prevention or treatment of cancer. The, total 100 parts by weight of said beverage derivatives pharmaceutical compositions, 0. 1 To 50 parts by weight of n, said fit surface beverage derivatives do not appear as cancer efficacy or range number, the amount of contrast line to which insignificantly higher at the therapeutic effectiveness of content isn't very sharp. Said arm is a basis, on androsyny transgenic animals, transgenic animals malignant, pituitary exaggeration, brain meningioma, brain lymphoma, [...], intracranial racially, such transgenic animals on, brain stem tumor, two neck areas tumor, cancer in, offering two cancers, nasal/sinus cancer, [...], various combinations cancer, low iron cancer, thyroid cancer, investigate, thoracic tumor, small cell lung cancer polystyrene, arsenic cell lung cancer, thymic cancer, tumor [...], esophageal cancer, breast cancer, male breast cancer, abdominal tumor, stomach cancer, liver cancer, gall bladder cancer, biliary tract cancer, pancreatic cancer, small intestine cancer, colon cancer, colorectal cancer, anal cancer, bladder cancer, renal cancer, male genital tumor, cancer of the penis, prostate cancer, female reproductive tumor, cervical cancer, endometrial cancer, ovarian cancer, uterine sarcoma, qualitative cancer, cancer mugwort female, female urethral cancer and skin cancer can be a the one or more selected from the group consisting 802.11a packets not one number. In addition, the present invention refers to formula 1 or formula 2 of beverage derivatives as effective ingredient for treatment or prevention of cancer disease to healthy foodstuffs including number [...] substrate. [Formula 1] Said R1 Hydrogen, (C2 - C4) alkyl carbonyl, alkoxycarbonyl (C1 - C4) benzoyl (Benzoyl) and is at least one selected from the group consisting of, [Formula 2] Said R2 Is hydrogen, (C1 - C4) alkyl carbonyl, alkoxycarbonyl (C1 - C4) benzoyl (Benzoyl) and by one or more selected from the group consisting of. Said pharmaceutical compositions gel number according to conventional method, oil number, scan number, acid number, number granules, aerosol number, paste number, number and patch number COOM group consisting of one or more selected from the group consisting number but can be ball-number, the one number are not disclosed. In the embodiment of the present invention in particular, said pharmaceutical compositions and production number commonly used pharmaceutical compositions suitable carrier, excipient number, number disintegrating, sweetener number, coating number, expansion number, lubricating number, number [...], flavor number, number antioxidant, buffer, bacteriostatic number, dilution number, dispersion number, number surfactants, selected from the group consisting of number and lubrication number coupled at an add-on can be further includes a number. Specifically, carrier, excipient is peak number and dilution number lactoperoxidase, dextran lactose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methylcellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methyl hydroxy benzoate, propyl hydroxy benzoate, talc, magnesium stearate and mineral fluid is used can be, positive number number number is solid for oral administration, ring number, acid number, number granules, such as included in a capsule number, said at least one excipient composition is such solid number number number, for example, starch, calcium purification, sucrose or lactose, gelatin can number tank pressure is lowered. In addition number [...] magnesium in addition to simple excipients, such as are also using lubricating number can be talc. For liquid oral suspension include number number number, number content, oil number, syrup or the like number and a simple dilution number commonly used in water, in addition to the paraffin droplet number various excipients, for example wet number, sweetener number, direction number, number and the like can be preserved. For parental administration number number is a sterile aqueous solution, non-aqueous for number, number suspension, oil number, freeze-dried number number, number and the like left multiple myelomas are included. Non-aqueous for number, number suspension include propylene glycol, polyethylene glycol, vegetable oil such as olive oil, such as the [ley which comes the [thu and ethyl ester is used as the injectable can be. Number of substrates include above [theyp brush left (witepsol), mark with goal, twin (tween) 61, carcass five fingers, that it soaked, can be characteristically preparing number is used as the alkali. Said beverage derivatives the preferred dosage is subject state and body weight, type and extent of diseases, forms, depending on the stated time can be appropriately selected by one skilled routes can be. In the embodiment of the present invention according to one, the number 1 but not one dose 0. 01 To 200 mg/kg, specifically 0. 1 To 200 mg/kg, more specifically 0. 1 To 100 mg/kg implementation being. Administration may be once per day administration may be divided into many times administration, the number range of the present invention are not disclosed. In the present invention, said 'subject' a can be a mammal including humans, not the limited to these instances. Said health foods powder, granules, positive number, capsule, syrup or beverage can be in the form of ball number, said health foods and other food or food additive in addition to the active ingredient and beverage derivatives used with, can be suitable for use according to the conventional method. Of effective ingredient mixing german silver of use object e.g. prevention, health or therapeutic treatment can be determined to be appropriate. Said health food effective capacity is included in said pharmaceutical composition effective capacity but are then identified by using melatonin derivatives, health and hygiene purposes or in the case of ingestion of said health control range and can have a long term is hereinafter, as the active ingredient in an amount of at least insofar as said safety door number because the range the engine can also be used reliably disclosed. Said type of number one health food is simplified and free, include meat, sausage, bread, chocolate, candy, [...], confectionery, pizza, if, other noodles, gum type, ice cream acid number a dairy product, various sprocket, beverage, difference, drinkable number, such as alcoholic beverages and vitamin composite number is cited. Said ointment skin cosmetic composition, based cosmetic, makeup cosmetic, shaving cosmetic or body for use as cosmetics or the like can be ball number, is applied on the examples of essence, lotion, cream, gel, water, pack, massage cream, emulsion and the like in which, said examples of cosmetic makeup foundation, lipstick, child [syay, Eyeliner, mascara, oh eve low pencil, make-up base or the like can be, body cosmetic include soap, liquid cleansing number, bathing number, the window screen cream, of opening the window may be oils and the like and, after shaving cosmetic include [syey eve lotion, shaving cream etc.. In addition, melatonin derivatives in addition to said cosmetic composition for improving properties further functional material or excipient number, substance such as dilution number can be included. Specifically, said cosmetic composition properties for enhanced perfume, dye, sterilization number, anti-oxidation number, number of a hydantoin, moisturizing number, number permanently, an inorganic salt or synthetic polymer substance or the like can be further added. In addition to formulation ingredient to a ferroelectric can also maintaining component, [...] number, number surfactants, organic pigment, inorganic pigment, organic powder, ultraviolet absorbing number, number adjusting pH, alcohol, patch number, arctium number, number or be a positive number water or a number. Active ingredient formulation component other than said defined to a ferroelectric can not, without impairing the effect and purpose of the invention the component within a range to which said pivotably combined. In addition, said cosmetic composition solution, emulsions, such as viscous type mixture can be shaped, typically the art any number type may be in one embodiment the number bath spray, emulsion, cream, water, pack, foundation, lotion, cosmetic liquid, such as the hair cosmetic can be a type number. More specifically of the present invention cosmetic composition spray, soap, cleansing foam, cleansing lotion, cleansing cream, body lotion, body cleanser, skin lotion, skin small [phu you, skin toner, oh [su tree [ceyn, lotion, milk lotion, [...] lotion, plant, massage cream, encapsulated into, feed [su department cream, hand cream, foundation, selected from the group, number type can be selected from the group comprising of electronic and nutrition. For example, when lactose carrier ingredient of the present invention number type spray or powder, talc, silica, aluminum [...], calcium silicate or polyamide powder can be used, in particular of the present invention number type this spray case additionally chloro [...], propane/butane or dimethyl ether can be such as to expel the projectile. Of the present invention number type paste, cream or when it is a gel carrier ingredient animal fiber, plant fiber, wax, paraffin, starch, space [thu coating, cellulose derivative, polyethylene glycol, silicon, bentonite, silica, talc or zinc oxide or the like can be used. In the case of carrier ingredient solution or emulsion of the present invention number type solvent, solvating number, or device for number is used, for example water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, 1, 3 - butyl glycol oil, glycerol aliphatic ester, be a polyethylene glycol or sorbitan fatty acid esters. Of the present invention number type suspension carrier ingredient when water, such as ethanol or propylene glycol liquid dilution number, box-ethoxylated alcohol, polyoxyethylene sorbitol esters and polyoxyethylene sorbitan ester such as suspension number, microcrystalline cellulose, aluminum meta [...], bentonite, agar or coating such as space [thu can be used. The interface type of the present invention number when a carrier ingredient containing cleansing - active number aliphatic alcohol sulfate, aliphatic alcohol ether sulfate, sulfonyl succinic ester, cleanser, imidazole [...] derivatives, methyl [...], cooperates with nose sour this [thu, fatty acid amide ether sulfate, alkyl polyglycoside, aliphatic alcohol, fatty acid glyceride, fatty acid d ethanol amide, vegetable oil, ethoxylated glycerol fatty acid ester can be used it teased derivative or the like. Hereinafter, for example in the embodiment of the present invention to aid in understanding detailed the on-sensors other. In the embodiment of the present invention is to form a nitride content of the present invention exemplified in the embodiment has the range only to limited to, art to entire surface with average knowledge [...] number to illustrate the present invention are disclosed. In the embodiment 1<>beverage preparation and beverage derivatives synthesis Also shown in beverage derivative compounds number 1 for high pressure liquid coolant, Compound 1Are stored in a Tokyo Chemical Industry/Japan after, a compound 1 reacting a 3 to 5 along and copiers. In addition beverage (Compound 2) Preparing a purchase in his Sigam Aldrich. [Compound 1] 1. Compound 3 synthesis Along said reactive 1, compound 1 in 5 - pineal gland (5 a-Methoxytryptamine, 100 mg, 0. 53 Mmol) triethylamine (triethylamine) and to [...] (butylchloride, 0. 83 Ml, 0. 79 Mmol) are reacted at ambient temperature after a period of time by adding, hops (ethyl acetate) and anhydrous MgSO (brine) and knife of extraction4 His drying and filtering. Filtration column chromatography (silica gel (silica gel), Hx: EtOAC=1:1) corrosion resistance or concentrated with e to the positive number Compound 3 (121. 5 Mg, 88. 1% Yield) by Congress. 1 H-a NMR (500 MHz, CDCl3 ) Δ 7. 26 - 7. 24 (M, 1H), 7. 02 - 7. 00 (M, 2H), 6. 86 - 6. 85 (M, 1H), 3. 84 (S, 3H), 3. 60 - 3. 56 (M, 2H), 2. 93 - 2. 91 (M, 2H), 2. 09 - 2. 06 (M, 2H,), 1. 63 - 1. 58 (M, 2H), 0. 91 - 0. 88 Ppm (m, 2H). 2. Compound 4 synthesis Along said reactive 1, compound 1 in 5 - pineal gland (5 a-Methoxytryptamine, 100 mg, 0. 53 Mmol) triethylamine (triethylamine) and benzoyl chloride to (benzoylchloride, 0. 92 Ml, 0. 79 Mmol) are reacted at ambient temperature and after a period of time by adding hops (ethyl acetate) (brine) and anhydrous MgSO knife of extraction4 His drying and filtering. Column chromatography (silica gel, Hx: EtOAC=1:1) with e or concentrated within a chrominance filtering to the positive number Compound 4 (111. 6 Mg, 73% yield) are obtained. 1 H-a NMR (500 MHz, CDCl3 ) Δ 7. 87 - 7. 86 (M, 2H), 7. 67 - 7. 64 (M, 1H), 7. 59 - 7. 56 (M, 2H), 7. 47 - 7. 45 (M, 1H), 7. 25 (M, 1H), 7. 08 - 7. 05 (M, 1H), 6. 49 - 6. 47 (S, 1H), 4. 01 - 3. 98 (M, 2H), 3. 97 (S, 3H), 3. 27 - 3. 25 Ppm (m, 2H,). 3. Compound 5 synthesis Along said reactive 1, compound 1 in 5 - pineal gland (5 a-Methoxytryptamine, 100 mg, 0. 53 Mmol) triethylamine (triethylamine) and di - [...][...] - dicarboxylic acid to carbonate (di - 1 H-a NMR (500 MHz, CDCl3 ) Δ 7. 24 - 7. 22 (M, 1H), 6. 86 - 6. 85 (M, 2H), 6. 84 (M, 1H), 3. 85 (S, 3H), 3. 45 - 3. 44 (M, 2H), 2. 91 - 2. 89 (M, 2H), 1. 42 Ppm (s, 9H). 4. 6 Compound synthesis Compound 6 is known document (G. In addition Spadoni 11 name, [Compound 2] 4. 7 Compound synthesis Along said reactive 2, said compound 6 (100 mg, 0. 53 Mmol) triethylamine to (triethylamine), acetyl chloride (acetylchloride, 0. 56 Ml, 0. 79 Mmol) after a period of time by the addition of a reacted at ambient temperature, (ethyl acetate) and anhydrous MgSO (brine) extraction and knife of hops4 His drying and filtering. Column chromatography (silica gel, Hx: EtOAC=1:1) with e or concentrated within a chrominance filtering to the positive number Compound 7(95. 4 Mg, 77. 5% Yield) by Congress. 1 H-a NMR (500 MHz, CDCl3 ) Δ 7. 21 - 7. 19 (M, 1H), 7. 00 - 6. 99 (M, 1H), 6. 99 - 6. 97 (M, 1H), 6. 19 (S, 1H), 3. 82 (S, 3H), 3. 60 - 3. 56 (M, 2H), 2. 96 - 2. 94 (M, 2H), 1. 93 Ppm (s, 3H). 5. 8 Compound synthesis Along said reactive 2, said compound 6 (100 mg, 0. 53 Mmol) triethylamine (triethylamine) to, [...] chloride (butylchloride, 0. 83 Ml, 0. 79 Mmol) are reacted at ambient temperature and after a period of time by adding hops (ethyl acetate) (brine) and anhydrous MgSO knife of extraction4 His drying and filtering. Column chromatography (silica gel, Hx: EtOAC=1:1) with e or concentrated within a chrominance filtering to the positive number Compound 8(99. 3 Mg, 72% yield) by Congress. 1 H-a NMR (500 MHz, CDCl3 ) Δ 7. 20 - 7. 18 (M, 1H), 6. 99 (M, 1H), 6. 78 - 6. 77 (M, 1H), 6. 18 (S, 1H), 3. 82 (S, 3H), 3. 61 - 3. 57 (M, 2H), 2. 96 - 2. 93 (M, 2H), 2. 11 - 2. 08 (M, 2H), 1. 64 - 1. 57 (M, 2H), 0. 90 - 0. 87 Ppm (m, 3H). 6. Compound 9 synthesis Along said reactive 2, said compound 6 (100 mg, 0. 53 Mmol) triethylamine to (triethylamine), benzoyl chloride (benzoylchloride, 0. 92 Ml, 0. 79 Mmol) after a period of time by the addition of a reacted at ambient temperature, (ethyl acetate) and anhydrous MgSO (brine) extraction and knife of hops4 His drying and filtering. Column chromatography (silica gel, Hx: EtOAC=1:1) with e or concentrated within a chrominance filtering to the positive number Compound 9(138. 5 Mg, 87% yield) are obtained. 1 H-a NMR (500 MHz, CDCl3 ) Δ 7. 69 - 7. 67 (M, 2H), 7. 48 - 7. 46 (M, 1H), 7. 40 - 7. 37 (M, 2H), 7. 20 - 7. 19 (M, 1H), 7. 00 (M, 1H), 6. 79 - 6. 77 (M, 1H), 6. 24 (S, 1H), 3. 82 (S, 3H), 3. 80 - 3. 77 (M, 2H), 3. 08 - 3. 05 Ppm (m, 2H). 7. Compound 10 synthesis Along said reactive 2, said compound 6 (100 mg, 0. 53 Mmol) triethylamine (triethylamine) to, [...][...] - dicarboxylic acid di - carbonate (di - 1 H-a NMR (500 MHz, CDCl3 ) Δ 7. 19 - 7. 14 (M, 1H), 7. 00 (M, 1H), 6. 78 - 6. 76 (M, 1H), 6. 19 (S, 1H), 3. 82 (S, 3H), 3. 47 - 3. 45 (M, 2H), 2. 94 - 2. 92 (M, 2H), 1. 41 Ppm (s, 9H). 8. Matching compound synthesis A compound generally along a MB-a 3 MB-a 2 and 3 contrast compound-configurated. [Compound 3] 8 - 1) Compound MB-a 2 synthesis Along said reactive 3, said compound 2 (157 mg, 0. 67 Mmol) and lithium aluminum hydride in tetrahydrofuran mixable (tetrahydrofuran, THF, 5 ml) (lithium aluminium hydride, 1. 4 Ml, 1. 35 Mmol) added while agitating after reacting heating, water (2. 5 Ml) was added to terminate the reaction. Hops (ethyl acetate) and anhydrous MgSO (brine) extraction and knife of same4 His drying and filtering. Column chromatography or concentrated within a chrominance filtering with e (silica gel, dichloro methane (CH2 Cl2 ): Methanol (MeOH)=9:1 (1% ammonia (NH3 OH))) positive number to the white solid MB-a 2(89. 7 Mg, 61% yield) are obtained. 1 H-a NMR (500 MHz, CDCl3 ) Δ 7. 22 (S, 1H), 7. 21 7 (S, 1H). 06 (M, 1H) 7. 01 (M, 1H), 6. 81 - 6. 79 (M, 1H), 3. 26 - 3. 23 (M, 2H), 3. 14 - 3. 11 (M, 2H), 2. 98 - 2. 93 (M, 2H), 1. 36 - 1. 33 Ppm (m, 3H). 8 - 2) Compounds MB-a 3 synthesis Along said reactive 3, said compound 3 (386 mg, 1. 48 Mmol) and lithium aluminum hydride in tetrahydrofuran mixable (tetrahydrofuran, THF, 5 ml) (lithium aluminium hydride, 1. 4 Ml, 2. 94 Mmol) while heating after a period of time by the addition of a water agitating reacting (2. 5 Ml) was added to terminate the reaction. Hops (ethyl acetate) and anhydrous MgSO (brine) extraction and knife of same4 His drying and filtering. Column chromatography or concentrated within a chrominance filtering with e (silica gel, CH2 Cl2 : MeOH=9:1 (1% NH3 OH)) positive number to the white solid MB-a 3(231. 4 Mg, 63. 4% Yield) are obtained. 1 H-a NMR (500 MHz, CDCl3 ) Δ 7. 18 (S, 1H), 7. 24 - 7. 20 (M, 2H), 7. 04 - 6. 75 (M, 1H), 6. 85 (S, 1H), 6. 75 - 6. 73 (M, 1H), 3. 73 (S, 1H), 3. 12 - 3. 11 (M, 2H), 2. 98 - 2. 95 (M, 2H), 2. 70 - 2. 67 (M, 2H), 1. 63 - 1. 56 (M, 2H), 1. 24 - 1. 20 (M, 4H), 0. 79 - 0. 76 Ppm (m, 3H). 4 Contrast compound along with a compound MLB-a 2 and a configurated MLB provided 3. [Compound 4] 8 - 3) Compound MLB provided 2 synthesis Along said reactive 4, said compound 7 (150 mg, 0. 64 Mmol) and lithium aluminum hydride in tetrahydrofuran mixable (tetrahydrofuran, THF, 5 ml) (lithium aluminium hydride, 1. 3 Ml, 1. 29 Mmol) while heating after a period of time by the addition of a water agitating reacting (2. 5 Ml) was added to terminate the reaction. Hops (ethyl acetate) and anhydrous MgSO (brine) extraction and knife of same4 His drying and filtering. Column chromatography or concentrated within a chrominance filtering with e (silica gel, CH2 Cl2 : MeOH=9:1 (1% NH3 OH)) positive number to the brown solid MLB-a 2(84 Mg, 60% yield) are obtained. 1 H-a NMR (500 MHz, CDCl3 ) Δ 7. 24 - 7. 19 (M, 2H), 7. 04 (S, 1H), 6. 93 (S, 1H), 6. 77 - 6. 75 (M, 1H), 3. 75 (S, 3H), 3. 20 - 3. 18 (M, 2H), 3. 08 - 3. 07 (M, 2H), 2. 91 - 2. 90 (M, 2H), 1. 32 - 1. 30 Ppm (m, 3H). 8 - 4) Compound MLB provided 3 synthesis Along said reactive 4, said compound 8 (200 mg, 0. 76 Mmol) and lithium aluminum hydride in tetrahydrofuran mixable (tetrahydrofuran, THF, 5 ml) (lithium aluminium hydride, 1. 5 Ml, 1. 52 Mmol) while heating after a period of time by the addition of a water agitating reacting (2. 5 Ml) was added to terminate the reaction. Hops (ethyl acetate) and anhydrous MgSO (brine) extraction and knife of same4 His drying and filtering. Column chromatography or concentrated within a chrominance filtering with e (silica gel, CH2 Cl2 : MeOH=9:1 (1% NH3 OH)) positive number to the brown solid MLB provided 3(109. 9 Mg, 63. 4% Yield) are obtained. 1 H-a NMR (500 MHz, CDCl3 ) Δ 7. 23 (S, 1H), 7. 10 - 7. 09 (M, 1H), 7. 04 (S, 1H), 3. 81 (S, 3H), 3. 34 - 3. 32 (M, 2H), 3. 21 - 3. 17 (M, 2H), 2. 93 - 2. 89 (M, 2H), 1. 34 - 1. 30 (M, 4H), 0. 85 - 0. 82 Ppm (m, 3H). 8 - 5) Compound MC-a 1 synthesis [Compound 5] Along said reactive 5, compound 1 in 5 - pineal gland (5 a-Methoxytryptamine, 500 mg, 2. 63 Mmol) N - [...] to carbonate (N provided carbobenzoxyglycine, 1. 1 G, 5. 3 Mmol), 1 - ethyl - 3 - (3 - dimethylamino-propyl) carbodiimide ((3 a-dimethylaminopropyl) 1 a-Ethyl provided 3 - carbodiimide, EDCI, 1. 0 G, 5. 3 Mmol), triethylamine (triethylamine, 364. 3 Μl, 2. 6 Mmol), 4 - dimethylamino pyridine (4 a-dimethylaminopyridine, DMAP, 32. 1 Mg, 0. 26 Mmol) dichloro methane (dichloromethane, 13 ml) at room temperature was added 30 minutes and reacting. Then hops (ethyl acetate) and anhydrous MgSO (brine) extraction and knife of same4 His drying and filtering. Column chromatography (silica gel, Hx: EtOAC=1:1) positive number or concentrated within a chrominance filtering with e to the brown solid Compound 11(901 Mg, 90% yield) by Congress. Said compound 11 (300 mg, 0. 79 Mmol) and Pd (OH)2 /C (11. 1 Mg, 0. 08 Mmol) mixing, methanol (2. 6 Ml) and hydrogen (H2 ) Of his a. 2 2000 Hours in the atmosphere which it will peel a write (Cellite) to fill the filtration under reduced pressure MeOH (100 ml) was pressure to filtering. After filtration under vacuum conditions or concentrate dichloro methane (5 ml) and methanol (1 ml), acetyl chloride (1 ml) of the anode stirs hydrogen chloride (hydrogen chloride, 1 ml) slowly a number of his high pressure liquid coolant. Same then hops (100 ml) performed more than once to pressure filtration of the white solid MC-a 1(189. 4 Mg, 97% yield) are obtained. In the embodiment 2<>beverage and beverage derivatives identifying anti-inflammatory Said beverage and to make sure that the melatonin derivatives synthesized in inflammatory effects in the embodiment 1, first Raw 264. 7 Cells obtained Korean cell line bank (Korean Cell Line Bank; KCLB) (Fetal bovine serum, FBS, Gibco BRL) 10% fetal [...], 100 U/ml/100 μg/ml erythromycin penicillin-resistant Streptococcus) included in the cell culture medium (Dulbecco's Modified Eagle's, DMEM, Gibco BRL) was. Lipid polysaccharide (Lipopolysaccharide, LPS) and grease (Griess) reagents are sigma (Sigma non-Aldrich) was used in seller. In the presence of 1 μg/mL LPS Raw 264. 7 Cells into a processing material is a synthesized in said beverage and in the embodiment 1 lie group reagent by the RIE processing group 24 hours was preparing a model inflammatory processing melatonin derivative. 1. Generating NO billion number identifying cytotoxic effect Prepare the beverage and beverage derivatives prepared on the inflammatory model in said said in the embodiment 1 (nitrite) culture medium nitrite concentration by treating amount to 540 nm absorbance in a side anti-inflammatory (Griess) reagents grease therefrom. Nitric oxide (NO) generating analysis is already publicly known method (Hwang, S. J. , Y. W. Kim, Y. Park, H. J. Lee, K. W. Kim. 2014 Anti non-inflammatory effects of chlorogenic acid in lipopolysaccharide-a stimulated RAW 264. 7 Cells. Inflammation research 63:81 - 90.) is conducting. As a result also such as 2, 2 of Figure 1 compound in a number depending on generation of all beverage derivative concentration existing beverage than NO [...] melatonin billion number out an excellent effect. In addition beverage derivatives in order to identify whether the cytotoxic effect by generating NO billion number, cell survival rates has been confirmed. The method already publicly known (Hwang, S. J. , Y. W. Kim, Y. Park, H. J. Lee, K. W. Kim. 2014 Anti non-inflammatory effects of chlorogenic acid in lipopolysaccharide-a stimulated RAW 264. 7 Cells. 2. Identifying inflammatory factor billion number effect Prepare a location 1, 3 or 7 said in the embodiment 2 in inflammation model beverage derivatives, inflammatory cytokine is monocyte Chemotactic protein -1 (monocyte chemoattractant protein provided 1, MCP-a 1), IL provided 6, IL-a beta 1, to RT a-PCR confirmed expression of COX-a 2 and TNF a-α. RT-a PCR analysis is already publicly known method (Hwang, S. J. , Y. W. Kim, Y. Park, H. J. Lee, K. W. Kim. 2014 Anti non-inflammatory effects of chlorogenic acid in lipopolysaccharide-a stimulated RAW 264. 7 Cells. Inflammation research 63:81 - 90.) is conducting. PCR primer used in the present invention and represented such as table 1, was stored in it comes at all oh (Bioneer). For PCR amplification confirmation, β - 1 by using an internal control expression vector PCR product. 5% Agarose gel (RedSafe nucleic acid staining, Intron, Korea) separating means for visualizing the UV is irradiated red safe nucleic acid dyeing has been confirmed. As a result, as shown in fig. 3, MCP-a 1, IL provided 6, COX-a 2, TNF a-α significantly reduced the expression of these markers. The present invention according to the melatonin derivative represented by the following a clause salt effect is better than melatonin has been confirmed. In the embodiment 3 Compound 48/80 induced histamine secretion billion in identifying number effect<>mast cell Said beverage derivatives billion number effect histamine for separate, non-lifting maneuvers that University immunology classroom and his completed a first [...] university eternity [...] HMC-a 1 human, 10% fetal right serum (fetal bovine serum, FBS)/1% penicillin-resistant Streptococcus pneumoniae and Streptococcus feed (penicillin/streptomycin) on the husk (Iscove's Modified Dulbecco's Media) containing 5% CO₂ IMEM 37 °C him as conditions. The HMC-a 1 3 × 10 cultured6 Prepare the beverage and beverage derivatives in said in the embodiment 1 in 30 minutes 37 °C v0. processing load in a predetermined, 300 μg/ml was added to a 20 minutes by reacting Compound 48/80. Compound 48/80 cells have the small centrifuging the supernatant processing wastes, histamine is included supernatant on O - by reacting aldehyde phthalides (O a-phthaladehyde, OPT) were measured. I.e., supernatant is positioned for measuring the amount of histamine (histamine) 0 to 500 μl supernatant. 5N perchlorate (HClO4 ) 20 Minutes in 2 ml was mixed into 12,000 rpm after centrifuging. 2 Ml 6N sodium hydroxide (NaOH) centrifuging the supernatant to 0. 2 Ml, butanol - chloroform (buthanol non-chloroform (3:2)) 3. 3 Ml sodium chloride (NaCl) in 10 minutes was placed on 3,000 rpm and centrifuging. After centrifuging the supernatant to an upper layer 3 ml 3 ml n - heptane (n-a heptane) to 0. 1N hydrogen chloride (HCl) 1. After 5 minutes 10 minutes in 2 ml mixed into 100 °C is possible then to 3,000 rpm in a centrifuge [...] pipette was collecting the underlying layer. 0 Solution upside down. 1N HCl 1 ml and 1N NaOH 0. 3 Ml, 0. 2% OPT 0. 2 Ml in 45 minutes into the reaction then leucorrhea cow, 0. 5N sulfate (H2 SO4 ) 0. 28 Ml into fluorescent light (Spectrofluorophotometer, Shimadzu, Japan) is reacted to terminate herein with a 350 nm (excitation) after measuring, 440 nm emission (emission) using quartz in queue [peys fluorescent amount were measured. As a result, as shown in at least two 1, 3, 7 billion number as beverage derivatives is also 4 histamine was observed, in particular in the case of beverage using ar number effect histamine billion at 7 melatonin derivatives has been confirmed. Identifying cancer<>beverage and beverage derivatives in the embodiment 4 1. In a colon cancer cell line HCT116 identifying anticancer activity in vitro Prepare the beverage and beverage derivatives in colon cancer cell line HCT provided 116 said in the embodiment 1 to verify that the anticancer effect for the bud which will doze bromide (Thiazolyl Blue Tetrazolium Bromide, MTT) analyzed by cell survival under the blue 2 thiazolly facia, publicly known to this end is synthesized (Lee H a-Y et al. , (2013) Cancer Lett. 332:102 - 109) Used as a method to conducting experiments as follows. Colon cancer cell line HCT provided 116 cell bank was prepared in agriculture. HCT-a 116 cells by heat inactivated 10% small [thay [...] (Fetal Bovine Serum, FBS), 100 units/mL penicillin-resistant Streptococcus pneumoniae (penicillin), 100 μg/mL amphotericin B Streptococcus feed (streptomycin) and 250 ng/mL (amphotericin B) is included in the optimum medium 37 °C RPMI 1640, 5% carbon dioxide (CO2 ) Conditions 1 to 2 times to 1 weeks passaging on him. Liquid nitrogen then all cells from 3 or more times via passaging melting and then experiments using the air. 96 - Well plates by said colon cancer cell lines each well 200 micro l (2 x 104 Cells/ml) which is included in the him as during day. (Dimethyl sulfoxide, DMSO) next dimethyl opinion width hour freight to beverage and beverage derivatives 0. At a concentration of 2 mm to 125 mm adding him as liver 3. Stage, is to not more than 10% DMSO is free medium was used. Sample processing voice controls (zero-a day control) as well as the group consisting only without DMSO. 20 Μl of 5 mg/ml MTT solution culture cells 4 and further processing time preventing problems, phosphate buffer saline solution (phosphate buffered saline, PBS) number into a number after a stand-alone medium and then to apply DMSO 200 μl been stand-alone. 15 Minutes then 590 nm were measured absorbance in stirrer in it agitated. Comparing the group when cultured in 10% DMSO to each test substance processing according to cell survival rate were measured using a mathematical equation 1. [Mathematical equation 1] =% survival rates (OD - OD (sample) (0 a-day))/(OD (10% DMSO) - OD (0 a-day)) X 100 A finish which gives 100% regulated sample, sample treating group regulated percentage value for precursor, double or triple test is determined average value of each test substance treatment been ± SEM. IC50 Value is 50% survival rates for altering test are disclosed. As a result, such as beverage derivatives also 5 7, MB-a 2, and a number of beverage than showed excellent anticancer effect both [...] MC-a 1. In particular 1 mm hereinafter concentration significant anticancer activity even 10 times have shown significant derivatives precursor among anticancer activity. 2. Cervical cancer, breast cancer, lung cancer, colon cancer cell lines for identifying anticancer In identifying the beverage 10 times derivatives that said in the embodiment to human cervical cancer, breast cancer, lung and colon cancer cell lines (Thiazolyl Blue Tetrazolium Bromide) for anticancer effect of MTT 1 during said in the embodiment 4 described has been confirmed. Human uterine cancer cell lines HeLa, A549 lung cancer cell lines on breast cancer cell lines (ATCC, Manassas, VA, USA) is a dielectric ceramic cell lines MDA-a MB-a 231 was completed in bank. HCT116, HeLa, A549 cells inactivated by heat and MDA-a MB-a 231 [...] small [thay 10% (Fetal Bovine Serum, FBS), 100 units/mL penicillin-resistant Streptococcus pneumoniae (penicillin), 100 μg/mL amphotericin B Streptococcus feed (streptomycin) and 250 ng/mL (amphotericin B) is included in the optimum medium 37 °C RPMI 1640, 5% CO2 Conditions 1 to 2 weeks to 1 times involve passaging once was. Liquid nitrogen then all cells from 3 or more times via passaging melting and then experiments using the air. As a result, a wide range of derivatives such as beverage 10 times 6 also showed an anticancer effect. In particular lung cancer cell lines [...] number remaining colon cancer, breast cancer, cervical cancer cell lines have shown significantly superior in beverage compared to anticancer activity. 3. Beverage derivatives indicates that before an anticancer effect molecular analysis Beverage derivatives indicates that to analyze the colon cancer cell line HCT provided 116 is an anticancer effect molecular mechanisms to prepare the beverage and beverage derivatives 1 to 10 in said in the embodiment 1 and the [wey the [su it shook off blot (western blot) has been confirmed that the cancer is processing. The [wey the [su it shook off analysis is already publicly known method (2014, As a result also such as 7, beverage derivatives cancer cell death (Apoptosis) number of cells such as cell growth billion acting as a protein kinase B (AKT) of signal transduction scheme because a billion number has been confirmed. In particular best anticancer activity once AKT phosphorylation of number 10 billion ability was derivatives also most transmission option. The hypoxic conditions over many regardless of cancer HIF-a 1 α increased activity. Rapid proliferation is cancer emitted from all parts which state its adaptation HIF-a 1 α activity but can be enhanced, chamber number by clause poetic proliferation signal transduction scheme is hypoxic conditions include a roof structure is increased so that the variant gene, persistent HIF-a 1 α increase activity state show other. In the treatment of cancer cells the expression of HIF-a alpha 1 very important disclosed. Said in the embodiment shown in Figure 3 of anticancer activity was relatively low for each cell line HCT provided 116 after processing a melatonin derivatives 1, 3, 7, 8, expression of hypoxic induction factor -1 α (Hypoxia non-inducible factor-a 1 alpha, HIF-a 1 alpha) has been confirmed. Specifically the [wey the [su it shook off the [...] conducting as follows: HIF-a 1a (BD), as well as the [thyu it soaked (Tubulin, Santa Cruz) protein specific primary antibodies. Anti mouse hall [su when the coupled secondary antibodies (mouse horseradish peroxidase) number [...][...] pierce chemical (Pierce Chemical Co.) stored in, electrochemiluminescence (ECL Plus reagent, Amersham Biosciences, USA) to (Electrogenerated ChemiLuminescence) plus reagent (Vilber Lourmat, FR) detected using color after fusion (Fusion) equipment. (Ponceau S) S phone small sigma (Sigma) was stored in solution. As a result also 8 such as, beverage derivatives are processed significantly reduced when the HIF provided 1 α expression when confirming, in particular derivatives 3 and 8 at once to further billion number has been confirmed that the existing beverage than HIF-a 1 α expression. Specific techniques of the present invention that are directionally-bar portion more precisely, to the party industry in person with skill in the art, only one such particularly preferred embodiment the procedure is received, the range of the present invention apparently is the number that are not one will. The substantial range of the present invention defined by appended claim and their equivalent that will. The present invention relates to a pharmaceutical composition, a health-aid food or a cosmetic composition comprising a melatonin derivative. When an inflammation model is treated with a melatonin derivative, anti-inflammatory activity is provided to inhibit production of NO and expression of inflammatory cytokines, and histamine secreted from mast cells is inhibited to suppress an allergic response mediated by histamine. When cancer cells are treated with a melatonin derivative, anti-cancer activity is provided to inhibit the signal transfer systems of protein kinase B (AKT) and extracellular signal-regulated kinase (ERK) and expression of hypoxia-inducible factor-1 alpha (HIF-1). Thus, the pharmaceutical composition according to the present invention is useful for a therapeutic agent, a cosmetic composition or a health-aid food for treating inflammatory diseases, allergic diseases or cancer diseases. Back number Back number Back number Back number Back number Formula 1 or formula 2 to pharmaceutical compositions for preventing or treating allergic disorders including of beverage derivatives as effective ingredient. [Formula 1] Said R1 Is hydrogen or propyl carbonyl and, [formula 2] Said R2 Methyl carbonyl by is. According to Claim 6, said beverage derivatives total 100 parts by weight of pharmaceutical compositions, 0. 1 To 50 parts by weight of the pharmaceutical composition for preventing or treating allergic disorders characterized. According to Claim 6, said bronchial asthma is allergic disorders (asthma), trihydroxyheptanoic (urticaria), drug it will bloom, [lak the cis (anaphylaxis), allergy (food allergy), about allergic (drug allergy), cost granulocytes transfusion reaction allergy, atopic dermatitis (atopic dermatitis). (Allergic rhinitis) allergic rhinitis, allergic conjunctivitis, allergic dermatitis, allergic contact dermatitis and wall margin selected from the group consisting of not more than pharmaceutical compositions for preventing or treating allergic disorders characterized. Formula 1 or formula 2 to of beverage derivatives as effective ingredient for treatment or prevention of allergic disorders including health food. [Formula 1] Said R1 Is hydrogen or propyl carbonyl and, [formula 2] Said R2 Methyl carbonyl by is. Formula 1 or formula 2 to of beverage derivatives as effective ingredient for treatment or prevention of allergic disorders including cosmetic composition. [Formula 1] Said R1 Is hydrogen or propyl carbonyl and, [formula 2] Said R2 Methyl carbonyl by is. Back number Back number Back number Back numberName Direction Sequence Sequence number IL-a beta 1 Forward (forward) Aagggctgcttccaaacctttgac 1 Reverse (reverse) Tgcctgaagctcttgttgatgtgc 2 TNF a-α Forward (forward) Catcttctcaaaattcgagtgacaa 3 Reverse (reverse) Tgggagtagacaaggtacaaccc 4 COX-a 2 Forward (forward) Ttcaaaagaagtgctggaaaaggt 5 Reverse (reverse) Gatcatctctacctgagtgtcttt 6 IL provided 6 Forward (forward) Gaggataccactcccaacagacc 7 Reverse (reverse) Aagtgcatcatcgttgttcataca 8 MCP-a 1 Forward (forward) Cttctgggcctgctgttca 9 Reverse (reverse) Ccagcctactcattgggatca 10 GAPDH Forward (forward) Gagctgaacgggaagctactgg 11 Reverse (reverse) Ccaccttcttgatgtcatcat 12
